These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 10811138

  • 61. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
    Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, Nelson C, Garrido C, So A, Fazli L, Bladou F, Gleave M, Iovanna JL, Rocchi P.
    Oncogene; 2010 Apr 01; 29(13):1883-96. PubMed ID: 20101233
    [Abstract] [Full Text] [Related]

  • 62. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo.
    Srikanth S, Kraft AS.
    Cancer Res; 1998 Feb 15; 58(4):834-9. PubMed ID: 9485043
    [Abstract] [Full Text] [Related]

  • 63. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave M, Miyake H.
    World J Urol; 2005 Feb 15; 23(1):38-46. PubMed ID: 15770517
    [Abstract] [Full Text] [Related]

  • 64. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Sirotnak FM, She Y, Lee F, Chen J, Scher HI.
    Clin Cancer Res; 2002 Dec 15; 8(12):3870-6. PubMed ID: 12473602
    [Abstract] [Full Text] [Related]

  • 65. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
    Teicher BA, Kakeji Y, Ara G, Herbst RS, Northey D.
    In Vivo; 1997 Dec 15; 11(6):453-61. PubMed ID: 9509295
    [Abstract] [Full Text] [Related]

  • 66. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, Gleave ME.
    J Pharmacol Exp Ther; 2001 Sep 15; 298(3):934-40. PubMed ID: 11504787
    [Abstract] [Full Text] [Related]

  • 67. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
    Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW.
    Cancer Res; 1999 Oct 01; 59(19):4761-4. PubMed ID: 10519379
    [Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
    DiPaola RS, Aisner J.
    Semin Oncol; 1999 Feb 01; 26(1 Suppl 2):112-6. PubMed ID: 10190792
    [Abstract] [Full Text] [Related]

  • 72. Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.
    Guinan P, Shaw M, Mirochnik Y, Slobodskoy L, Ray V, Rubenstein M.
    Methods Find Exp Clin Pharmacol; 1998 Nov 01; 20(9):739-42. PubMed ID: 10022026
    [Abstract] [Full Text] [Related]

  • 73. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
    Schatten H, Ripple M, Balczon R, Weindruch R, Chakrabarti A, Taylor M, Hueser CN.
    J Cell Biochem; 2000 Jan 01; 76(3):463-77. PubMed ID: 10649443
    [Abstract] [Full Text] [Related]

  • 74. Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells.
    Yang CC, Hsu CP, Yang SD.
    Clin Cancer Res; 2000 Mar 01; 6(3):1024-30. PubMed ID: 10741730
    [Abstract] [Full Text] [Related]

  • 75. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Endocrinology; 2000 Jun 01; 141(6):2257-65. PubMed ID: 10830316
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression.
    Kyprianou N, Rock S.
    Anticancer Res; 1998 Jun 01; 18(2A):897-905. PubMed ID: 9615738
    [Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
    Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG.
    Cancer Res; 1996 Jul 01; 56(13):3042-6. PubMed ID: 8674060
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.